Form 4: Edgewise Therapeutics Director Receives Stock Grant

Edgewise Therapeutics Director Jonathan C Fox was granted 473 shares of common stock as a quarterly retainer award.

Summary

• Jonathan C Fox, a Director at Edgewise Therapeutics, Inc. (EWTX), acquired 473 shares of common stock.
• The transaction occurred on January 2, 2026, and the shares were granted at a price of $0.00.
• The acquisition represents restricted stock units granted and released as a Quarterly Retainer Award.
• This award is pursuant to Section 2.4 of the Edgewise Therapeutics, Inc. Outside Director Compensation Policy, as amended.
• Following this transaction, Jonathan C Fox beneficially owns 24,175 shares of common stock.

Sentiment

Score: 7

Explanation: The filing reflects a routine and expected compensation event for a director, which is generally positive for corporate governance and alignment of interests, but does not provide new operational or financial insights.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of shareholders, promoting long-term value creation.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

Equity grants to outside directors are a common practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, serving to attract and retain qualified board members while aligning their incentives with shareholder value.

Comparison to Industry Standards

• The practice of compensating directors with equity, such as restricted stock units, is a widely adopted standard in corporate governance across industries, including biotech, to foster long-term commitment and align director interests with company performance and shareholder returns.
• Comparable companies often utilize similar equity-based compensation structures for their non-executive directors, reflecting best practices in corporate governance.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Jonathan C Fox, a Director, constitutes a related party transaction, which is disclosed and executed under the company's established Outside Director Compensation Policy.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with long-term shareholder value, potentially leading to more shareholder-centric decision-making.

Key Dates

Recommendation

This Form 4 filing details a routine grant of restricted stock units to a director as part of their compensation policy. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Such grants are standard practice to align director interests with shareholders.

Keywords

Edgewise Therapeutics, EWTX, Jonathan C Fox, Director Compensation, Stock Grant, Restricted Stock Units, Insider Transaction, Form 4